CClinicalTrials.gg
CompletedNCT03853629Updated Mar 10, 2020

Air Pollution and Children With Cystic Fibrosis

An observational study in Cystic Fibrosis, sponsored by Queen Mary University of London. Completed at 1 site in United Kingdom. Open to participants aged 1 Year to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-10.

Sponsored by Queen Mary University of London · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
1 Year to 17 Years
Sex
All
01

Study summary

  1. To determine personal exposure to air pollution in children with cystic fibrosis;
  2. To determine airway macrophage uptake of inhaled particulate matter in cystic fibrosis children;
  3. To establish whether prostaglandin E2 affects particulate matter removal in airway.
Read the detailed description

Background:

Cystic fibrosis (CF) is the commonest hereditary life-shortening respiratory condition, resulting in premature death secondary to recurrent airway infections and inflammation, leading to irreversible lung damage. The screening programme in infancy has improved life expectancy but the lifespan of CF patients is still reduced by 20 years at present. Thus interventions to reduce inflammation, infection and lung damage in CF are still needed.

One potential intervention is to reduce exposure of CF children to air pollution. Particulate matter (PM) are microscopic soot particles from petrol and diesel engine emissions; PM is linked to adverse respiratory health effects in children. Children with cystic fibrosis are particularly vulnerable to PM but, to date, no exposure-reduction advice is available, and the mechanism underlying this vulnerability is unclear.

Personal exposure of CF children to PM is due to: i) locally-generated sources (relative to the proximity to busy roads) and ii) background concentrations (i.e. PM blown across the whole city from other areas). Although a link between air pollution and reduced lung function growth in healthy children is well established, the link with CF lung disease has only recently emerged. A recent study found that long-term exposure of CF children to PM increases risk of airway infection with Pseudomonas. Another study also found that short-term background pollution is associated with increased need for antibiotics in children and adults with CF. The need to reduce patients' personal exposure to PM has been recognised by Barts Health NHS Trust. Working with Global Action Plan, the Trust has developed tips on how to reduce adults' personal exposure to air pollution. These tips include traveling outside rush hours, taking low pollution routes (maps provided), and signing up to the airText air pollution warning App. Since travel outside rush hours is not feasible for school children, child-friendly tips are urgently needed.

Recent research in asthma patients suggests a putative mechanism of impaired removal of inhaled PM. In the healthy lung, inhaled PM is quickly removed (phagocytosed) by airway macrophages (AM). AM patrol the surface of epithelial cells lining the airways; after taking up PM, they move up and out of the lung. Thus AM with normal phagocytic function act to both reduce PM exposure of other airway cells - including epithelial cells, and to ensure that PM does not accumulate in the lung. The amount of carbon particles in AM was previously used to assess the effects of long-term effects of exposure of healthy children and adults. The amount of black carbon (BC) in AM reflects the intrinsic capacity of AM to remove PM (phagocytic capacity). AM carbon is significantly lower in conditions such as severe asthma, where AM phagocytic capacity is impaired. Furthermore, a role for prostaglandin E2 (PGE2) in mediating impaired phagocytic function in asthma has been identified. First, PGE2 suppresses AM phagocytosis of urban PM in vitro; and second, children with severe asthma had increased urinary PGE2 metabolites. Shift of inhaled PM away from AM to other cells has the potential to stimulate interleukin-8 (IL-8) release by epithelial cells - a phenomenon observed in mouse, where inhalation of non-inflammatory particles produces significant airway neutrophilia when AM phagocytic function is impaired.

The hypothesis is that impaired handling of inhaled PM by AM contributes to vulnerability of children with CF to air pollution. Specifically, increased vulnerability to inhaled PM in children with CF is due to PGE2-mediated impairment of AM phagocytosis. The corollary is that children with CF will have; i) reduced levels of AM carbon in vivo (reflecting reduced phagocytosis of inhaled PM in vivo), ii) reduced capacity of AM to phagocytose carbon PM in vitro, iii) increased metabolites of PGE2 in the airway and urine, and finally, iv) since PGE2 production is under the control of the enzyme cyclooxygenase (COX, especially COX-2), CF airway cells have increased COX-2 expression, v) COX inhibitors (e.g. Ibuprofen) should suppress PGE2 production, theoretically improving AM function.

Non-cystic fibrosis bronchiectasis is a respiratory condition with multiple aetiology such as congenital pathology, immunodeficiency, and primary ciliary dyskinesia. Patients with non-CF bronchiectasis demonstrate similar clinical features to those with CF, patients with either conditions are managed with similar treatments, it is therefore hypothesised that the above also apply to children with non-CF bronchiectasis.

There has been evidence that some organisms are capable of reproducing and residing within airway macrophages without being destroyed by the traditional phagocytic pathway. Often, unwell CF and non-CF bronchiectasis patients are admitted to the hospital for intensive antibiotic treatments but a proportion of their sputum samples yield no growth by routine hospital culture. This study will explore isolated airway macrophages and identify the organisms within - if any are present.

Clinical Data:

There is evidence to support this hypothesis; i) it was previously reported that phagocytosis of inert latex beads is impaired in AM from CF adults (71 + 15 % phagocytosis in controls vs. 23 + 9 % in CF), ii), CF is associated with increased airway PGE2, and iii) in a pilot study, significantly (p\<0.01) reduced AM carbon in 6 CF children compared with 6 healthy controls (mean 0 vs. 0.3 + .05, μm2 p\<0.01) was found.

Rationale:

To date, the effect of impaired uptake of PM by AM on other airway cells has not been studied in vitro. The hypothesis is that in co-cultures of human AM and airway epithelial cells exposed to urban PM, PGE2-mediated impairment of macrophage phagocytosis increases epithelial release of IL-8. Furthermore, since AM are a major source of airway PGE2, it is speculated that there is increased COX-2 expression in AM from CF children. Thus suppression of AM phagocytic function in CF is an autocrine process; i.e. CF AM release more PGE2 - which in turn suppresses AM phagocytosis. In this study the evidence will be sought for abnormal handling of PM by AM from CF children, and model this using cultures of human airway cells and macrophages.

02

Conditions studied

  • Cystic Fibrosis
03

In context

Cystic Fibrosis

1,581 studies on the registry are indexed under Cystic Fibrosis; 190 are open to participants now.

This study's enrollment of 60 is below the median of 85 across 482 observational studies indexed under Cystic Fibrosis.

Browse Cystic Fibrosis studies →

Lead sponsor

Queen Mary University of London is the lead sponsor of 250 studies on the registry; 59 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Inclusion Criteria:

  • Age 1-17
  • Diagnosis of Cystic Fibrosis
  • Diagnosis of non-CF bronchiectasis
  • Living in or around London With age matched healthy controls

Exclusion Criteria:

  • Current active smoker
  • Receiving immunosuppressive drug therapy
  • For children with CF not on regular nebulised hypertonic saline: drop in FEV1 of >15% post-bronchodilator (exclusion criterion for sputum induction)
  • For healthy controls: Post-bronchodilator FEV1 \<80% (standard exclusion criterion for sputum induction in healthy individuals)
  • For participants currently or recently involved in other research study, they will be excluded if their current or recent research have any potential impact on our sampling or results.

Inclusion criteria

  • Age 1-17
  • Diagnosis of Cystic Fibrosis
  • Diagnosis of non-CF bronchiectasis
  • Living in or around London With age matched healthy controls

Exclusion criteria

Exclusion Criteria:

  • Current active smoker
  • Receiving immunosuppressive drug therapy
  • For children with CF not on regular nebulised hypertonic saline: drop in FEV1 of >15% post-bronchodilator (exclusion criterion for sputum induction)
  • For healthy controls: Post-bronchodilator FEV1 \<80% (standard exclusion criterion for sputum induction in healthy individuals)
  • For participants currently or recently involved in other research study, they will be excluded if their current or recent research have any potential impact on our sampling or results.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (actual)
Patient registry
No

Groups and cohorts

  • CF

    * Age 1-17 * Diagnosis of Cystic Fibrosis * Living in or around London

    Other: None. Not applicable

  • Controls

    * Age 1-17 * Healthy * Living in or around London

    Other: None. Not applicable

Interventions

  • OtherNone. Not applicable

    None. Not applicable

06

What researchers measure

Primary outcomes

  1. Airway macrophage uptake of inhaled particulate matter in both groups of children

    Black carbon loading area (micro-square meters) of airway macrophages, using light microscopy

    Time frame: 3 years

Secondary outcomes

  1. Personal exposure to air pollution in both groups of children

    Black carbon level (nanograms per cubic meter) of children's personal exposure - using an aethalometer.

    Time frame: 3 years

07

Study locations

1 site
  • Queen Mary University of London
    London, E1 2AT, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03853629
Lead sponsor
Queen Mary University of London
Responsible party
Sponsor
First posted
Feb 25, 2019
Start date
Feb 15, 2017
Primary completion
Jan 30, 2020
Completion
Jan 30, 2020
Last update
Mar 10, 2020

Study contacts

Jonathan Grigg
principal investigator · Queen Mary University of London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion